Overview

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Status:
Recruiting
Trial end date:
2023-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of the respiratory syncytial virus (RSV) maternal vaccine compared to placebo, when administered in the second or third trimester of pregnancy in women, 15 to 49 years of age (YOA), with high risk pregnancies and in the infants born to the vaccinated mothers.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline